Real-World Experience of Talimogene Laherparepvec (T-VEC) in Old and Oldest-Old Patients with Melanoma: A Retrospective Single Center Study
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Real-World Experience of Talimogene Laherparepvec (T-VEC) in Old and Oldest-Old Patients with Melanoma: A Retrospective Single Center Study
Authors
Keywords
-
Journal
Cancer Management and Research
Volume Volume 13, Issue -, Pages 5699-5709
Publisher
Informa UK Limited
Online
2021-07-14
DOI
10.2147/cmar.s286917
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB–IV M1c melanoma patients
- (2020) Anne Fröhlich et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Polypharmacy as a prognostic factor in older patients with advanced non-small-cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy
- (2020) Taiki Hakozaki et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- 1118P Retrospective analysis of safety in elderly BRAF V600 mutation-positive advanced melanoma patients treated with dabrafenib (D) and trametinib (T) and correlation with non-elderly patients
- (2020) A. García-Castaño et al. ANNALS OF ONCOLOGY
- High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a)
- (2019) Viola Franke et al. INTERNATIONAL JOURNAL OF CANCER
- Pembrolizumab for Unresectable or Metastatic Melanoma in Patients Older than 85 Years of Age
- (2019) Johan Chanal et al. DERMATOLOGY
- Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma
- (2019) Y J L Jansen et al. ANNALS OF ONCOLOGY
- Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
- (2019) O Hamid et al. ANNALS OF ONCOLOGY
- Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience
- (2019) Raphael J. Louie et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Health Care Resource Utilization and Costs in First-Line Treatments for Patients with Metastatic Melanoma in the United States
- (2019) Andrew J. Klink et al. Journal of Managed Care & Specialty Pharmacy
- Correlates of response and outcomes with talimogene laherperpvec
- (2019) Alice Y. Zhou et al. JOURNAL OF SURGICAL ONCOLOGY
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
- (2019) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune checkpoint inhibitors in older adults with melanoma or cutaneous malignancies: The Wilmot Cancer Institute experience
- (2019) William J. Archibald et al. Journal of Geriatric Oncology
- Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
- (2019) Robert H. I. Andtbacka et al. Journal for ImmunoTherapy of Cancer
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Economic Evaluation of Systemic Treatments for Advanced Melanoma: A Systematic Review
- (2019) Claire Gorry et al. VALUE IN HEALTH
- Efficacy of Talimogene Laherparepvec (T-VEC) Therapy in Patients with In-Transit Melanoma Metastasis Decreases with Increasing Lesion Size
- (2019) Sabran J. Masoud et al. ANNALS OF SURGICAL ONCOLOGY
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper
- (2018) Esther Bastiaannet et al. Journal of Geriatric Oncology
- Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study
- (2018) Tony Ibrahim et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Outcomes of elderly treated with pembrolizumab for metastatic melanoma comparing with younger patients.
- (2018) Caroline Dutriaux et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience
- (2018) Matthew C. Perez et al. ANNALS OF SURGICAL ONCOLOGY
- Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort
- (2018) M. Kandel et al. EUROPEAN JOURNAL OF CANCER
- Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
- (2017) Nigel Fleeman et al. PHARMACOECONOMICS
- Immunotherapy comes of age: Immune aging & checkpoint inhibitors
- (2017) Rawad Elias et al. Journal of Geriatric Oncology
- Review: Oncolytic virotherapy, updates and future directions
- (2017) Christos Fountzilas et al. Oncotarget
- What is polypharmacy? A systematic review of definitions
- (2017) Nashwa Masnoon et al. BMC Geriatrics
- Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis
- (2016) Tomohiro F. Nishijima et al. CANCER TREATMENT REVIEWS
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- Older Age is Associated with a Higher Incidence of Melanoma Death but a Lower Incidence of Sentinel Lymph Node Metastasis in the SEER Databases (2003–2011)
- (2015) Margaret W. Cavanaugh-Hussey et al. ANNALS OF SURGICAL ONCOLOGY
- Prognostic score for patients with advanced melanoma treated with ipilimumab
- (2015) Stefan Diem et al. EUROPEAN JOURNAL OF CANCER
- Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study
- (2014) James Larkin et al. LANCET ONCOLOGY
- The impact of comorbidity and stage on prognosis of Danish melanoma patients, 1987–2009: a registry-based cohort study
- (2013) A F Grann et al. BRITISH JOURNAL OF CANCER
- Cognitive decline after hospitalization in a community population of older persons
- (2012) R. S. Wilson et al. NEUROLOGY
- Projections of the Cost of Cancer Care in the United States: 2010-2020
- (2011) A. B. Mariotto et al. JNCI-Journal of the National Cancer Institute
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More